Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...

Clinicians are using dupilumab off label to treat a wider range of allergic conditions in adults and children. As the roster of approved and off-label indications grows, skin specialists said, ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...

Dupixent (dupilumab) is used to treat eczema that has not responded to topical medications. It’s approved for this use in adults and children ages 6 months and older. Some of Dupixent’s side effects ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

Please provide your email address to receive an email when new articles are posted on . Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce ...

The FINANCIAL — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic ...

An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways ...